Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Abstract AKS-452, a subunit vaccine comprising an Fc fusion of the ancestral wild-type (WT) SARS-CoV-2 virus spike protein receptor binding domain (SP/RBD), was evaluated without adjuvant in a single cohort, non-randomized, open-labelled phase II study (NCT05124483) at a single site in The Netherlan...

ver descrição completa

Detalhes bibliográficos

Principais autores:	David G. Alleva, Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero, Melanie M. Scully, Ramya Ragupathy, Sravya Kotha, Jeffrey R. Haworth, Nishit J. Shah, Vidhya Rao, Shashikant Nagre, Shannon E. Ronca, Freedom M. Green, Stephen A. Shaw, Ari Aminetzah, Schelto Kruijff, Maarten Brom, Gooitzen M. van Dam, Todd C. Zion
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-02-01
Colecção:	npj Vaccines
Acesso em linha:	https://doi.org/10.1038/s41541-024-00830-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!